Antihypertensive drug treatment changes in the general population: The colaus study

BMC Pharmacology and Toxicology

Volumn 15, Issue 1, 2014, Pages

  Christe, Vanessa ^a   Waeber, Gérard ^b   Vollenweider, Peter ^b   Marques Vidal, Pedro ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Antihypertensive drug therapy; Blood pressure; Combination; Discontinuation; Persistence; Prospective study; Switching; Switzerland

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBESITY; POPULATION RESEARCH; PRESCRIPTION; PROSPECTIVE STUDY; SWITZERLAND; SYSTOLIC BLOOD PRESSURE; BLOOD PRESSURE; DRUG UTILIZATION; MIDDLE AGED; PATHOPHYSIOLOGY; RISK FACTOR; STATISTICS;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIURETICS; DRUG UTILIZATION; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RISK FACTORS; SWITZERLAND;

EID: 84908134659     PISSN: None     EISSN: 20506511     Source Type: Journal    
DOI: 10.1186/2050-6511-15-20     Document Type: Article

References (29)

1. Elliott WJ, Plauschinat CA, Skrepnek GH, Gause D: Persistence, adherence, and risk of discontinuation associated with commonly prescribedantihypertensive drug monotherapies. J Am Board Fam Med 2007, 20(1):72-80
2. Danon-Hersch N, Marques-Vidal P, Bovet P, Chiolero A, Paccaud F, Pecoud A, Hayoz D, Mooser V, Waeber G, Vollenweider P: Prevalence, awareness, treatment and control of high blood pressure in a Swiss city general population: the CoLaus study. Eur J Cardiovasc Prev Rehabil 2009, 16(1):66-72
3. Bramlage P, Hasford J: Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment-a review. Cardiovasc Diabetol 2009, 8:18
4. Brenner R, Waeber B, Allemann Y: Medical treatment of hypertension in Switzerland. The 2009 Swiss Hypertension Survey (SWISSHYPE). Swiss Med Wkly 2011, 141:w13169
5. Brixner DI, Jackson KC 2nd, Sheng X, Nelson RE, Keskinaslan A: Assessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts in free-and fixed-dose combinations. Curr Med Res Opin 2008, 24(9):2597-2607
6. Bourgault C, Senecal M, Brisson M, Marentette MA, Gregoire JP: Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study. J Hum Hypertens 2005, 19(8):607-613
7. Mazzaglia G, Mantovani LG, Sturkenboom MC, Filippi A, Trifiro G, Cricelli C, Brignoli O, Caputi AP: Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens 2005, 23(11):2093-2100
8. Firmann M, Mayor V, Vidal PM, Bochud M, Pecoud A, Hayoz D, Paccaud F, Preisig M, Song KS, Yuan X, DanoffTM, Stirnadel HA, Waterworth D, Mooser V, Waeber G, Vollenweider P: The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome. BMC Cardiovasc Disord 2008, 8:6
9. Lean ME, Han TS, Morrison CE: Waist circumference as a measure for indicating need for weight management. BMJ 1995, 311(6998):158-161
10. Anatomical Therapeutic Chemical (ATC) classification system. http://www.whocc.no/atc/structure_and_principles/
11. 2009 Swiss Society of Hypertension Guidelines. http://swisshypertension. ch/guidelines.htm
12. Hypertension: Clinical Management of Primary Hypertension in Adults. http://publications.nice.org.uk/hypertension-cg127/guidance#choosingantihypertensive-drug-treatment-2
13. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, Dominiczak A, Narkeiwicz K, Nilsson PM, Burnier M, Viigimaa M, et al: 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013, 34(28):2159-219. doi: 10.1093/eurheartj/eht151. Epub 2013 Jun 14
14. Degli Esposti L, Degli Esposti E, Valpiani G, Di Martino M, Saragoni S, Buda S, Baio G, Capone A, Sturani A: A retrospective, population-based analysis of persistence with antihypertensive drug therapy in primary care practice in Italy. Clin Ther 2002, 24(8):1347-1357. discussion 1346
15. Veronesi M, Cicero AF, Prandin MG, Dormi A, Cosentino E, Strocchi E, Borghi C: A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice. Vasc Health Risk Manag 2007, 3(6):999-1005
16. Lachaine J, Petrella RJ, Merikle E, Ali F: Choices, persistence and adherence to antihypertensive agents: evidence from RAMQ data. Can J Cardiol 2008, 24(4):269-273
17. Aellig WH: Adverse reactions to antihypertensive therapy. Cardiovasc Drugs Ther 1998, 12(2):189-196
18. Gregoire JP, Moisan J, Guibert R, Ciampi A, Milot A, Cote I, Gaudet M: Tolerability of antihypertensive drugs in a community-based setting. Clin Ther 2001, 23(5):715-726
19. Chen K, Chiou CF, Plauschinat CA, Frech F, Harper A, Dubois R: Patient satisfaction with antihypertensive therapy. J Hum Hypertens 2005, 19(10):793-799
20. Sever PS, Messerli FH: Hypertension management 2011: optimal combination therapy. Eur Heart J 2011, 32(20):2499-2506
21. Friedman O, McAlister FA, Yun L, Campbell NR, Tu K, Canadian Hypertension Education Program Outcomes Research T: Antihypertensive drug persistence and compliance among newly treated elderly hypertensives in ontario. Am J Med 2010, 123(2):173-181
22. Bautista LE: Predictors of persistence with antihypertensive therapy: results from the NHANES. Am J Hypertens 2008, 21(2):183-188
23. Erkens JA, Panneman MM, Klungel OH, van den Boom G, Prescott MF, Herings RM: Differences in antihypertensive drug persistence associated with drug class and gender: a PHARMO study. Pharmacoepidemiol Drug Saf 2005, 14(11):795-803
24. Ho PM, Spertus JA, Masoudi FA, Reid KJ, Peterson ED, Magid DJ, Krumholz HM, Rumsfeld JS: Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med 2006, 166(17):1842-1847
25. Corrao G, Zambon A, Parodi A, Merlino L, Mancia G: Incidence of cardiovascular events in Italian patients with early discontinuations of antihypertensive, lipid-lowering, and antidiabetic treatments. Am J Hypertens 2012, 25(5):549-555
26. Weiss R, Buckley K, Clifford T: Changing patterns of initial drug therapy for the treatment of hypertension in a Medicaid population, 2001-2005. J Clin Hypertens (Greenwich) 2006, 8(10):706-712
27. Wong MC, Jiang JY, Griffiths SM: Switching of antihypertensive drugs among 93,286 Chinese patients: a cohort study. J Hum Hypertens 2010, 24(10):669-677
28. Wolf HK KK, Tolonen H, Ruokokoski E: Participation Rates, Quality of Sampling Frames and Sampling Fractions in the MONICA Surveys. In WHO MONICA; 1998. Available at www.thl.fi/publications/monica/nonres/nonres.htm assessed May 2013
29. Engel-Nitz NM, Darkow T, Lau H: Antihypertensive medication changes and blood pressure goal achievement in a managed care population. J Hum Hypertens 2010, 24(10):659-668